Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04424966 · ClinicalTrials.gov registry record · Early Phase 1
Infigratinib in Recurrent High-Grade Glioma Patients
A Early Phase 1 study, sponsored by Nader Sanai.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT04424966 is a Early Phase 1 study that was terminated before completion, run by Nader Sanai. The registered enrollment target is 7 participants.
The verdict
NCT04424966, a Early Phase 1 study, was terminated before completion, sponsored by Nader Sanai.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for resection. In the lead-in cohort, a total of 20 participants will be enrolled into the proposed phase 0 clinical trial. Participants will be administered infigratinib prior to surgical resection of their tumor.
Interventions
- DRUG Infigratinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-07-21 |
| Est. Completion | 2024-02-19 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04424966
The ClinicalTrials.gov registry entry for NCT04424966 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nader Sanai, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Infigratinib is the first listed.
NCT04424966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04424966 about?
NCT04424966 is a clinical study titled "Infigratinib in Recurrent High-Grade Glioma Patients". This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for resection. In the lead-in cohort, a total of 20 participants will be enrolled ...
What is the current status of trial NCT04424966?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2020-07-21. Estimated completion is 2024-02-19.
What interventions are being tested in trial NCT04424966?
The interventions under investigation include: Infigratinib (DRUG).
Who is sponsoring clinical trial NCT04424966?
This trial is sponsored by Nader Sanai, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.